Pharmacovigilance – News and Features

Warnex will provide pharmacogenetic and bioanalytical services for Novartis' Blood Level Monitoring Program for Gleevec®.

Athersys achieves important milestones in commercial collaborations with Bristol-Myers Squibb and Angiotech.

Osiris reports the results of a double-blind, placebo-controlled study evaluating the safety and preliminary efficacy of the intravenous administration an adult mesenchymal stem cell therapy.

The Resolver system will be used as a central data management and analysis system to evaluate the safety and toxicity of drugs submitted for FDA approval.

Medical College of Georgia researchers will use a test to measure a tumor's aggressiveness in more than 10,000 women to identify the patients who need chemotherapy.

Both the collaborators will develop a genetic test to aid in prescribing bucindolol, a genetically-targeted heart failure drug in development by ARCA.

Researchers aim to reveal the genetic and environmental causes behind deadly and disabling diseases.

Copernicus Therapeutics will utilize the funds for the development its non-viral gene therapy for cystic fibrosis.

The Company has initiated a safety trial using an animal model of Parkinson’s disease in primates utilizing its adult stem cell technology.

A research study identifies a common molecular trigger for the effects of toxicant exposure.